Muscle Growth peptides

18 peptides tagged muscle growth. Each page carries the dosing reference, mechanism, evidence grade and references.

PeptideLab is an educational platform for learning about peptides. The information here is for educational and research purposes only. It is not medical advice, diagnosis, or treatment, and PeptideLab does not claim to diagnose, treat, cure, or prevent any disease or health condition. Many peptides discussed have not been approved for human use by the FDA or other regulatory bodies. Consult a qualified healthcare professional before making any health-related decision.

  • ACE-031

    Soluble ActRIIB-Fc decoy receptor that binds myostatin and related ligands to increase muscle mass; human trials were halted over bleeding side effects.

    Evidence: Clinical

  • CJC-1295

    GHRH(1-29) analog carrying a Drug Affinity Complex that binds serum albumin, extending half-life to about a week and sustaining growth hormone and IGF-1 output.

    Evidence: Clinical

  • CJC-1295 + GHRP-2 Blend

    Vial blend of CJC-1295 without DAC (Mod GRF 1-29) and GHRP-2 (pralmorelin), 5 mg each; GHRP-2 raised GH and appetite in human studies, and no study has tested the pair.

    Evidence: Preclinical

  • CJC-1295 + GHRP-6 Blend

    Vial blend of CJC-1295 without DAC (Mod GRF 1-29) and GHRP-6, 5 mg each; GHRP-6 raised GH in men and synergized with GHRH, and no study has tested this pair.

    Evidence: Preclinical

  • CJC-1295 + Ipamorelin Blend

    Vial blend of CJC-1295 without DAC (Mod GRF 1-29) and ipamorelin, sold as 10 mg (5 mg each); the two act on separate GH-releasing receptors, and no study has tested the pair.

    Evidence: Preclinical

  • CJC-1295 no DAC (Mod GRF 1-29)

    Tetrasubstituted GHRH(1-29) analog ([D-Ala2, Gln8, Ala15, Leu27]), the peptide part of CJC-1295 without its albumin-binding linker; no published study of this exact peptide, each substitution characterized separately.

    Evidence: Preclinical

  • Follistatin-315

    Mature circulating form of follistatin (315 residues), a glycoprotein that binds activin strongly and myostatin weakly; muscle-mass gains come from transgenic and gene-transfer animals, not injected protein.

    Evidence: Preclinical

  • Follistatin-344

    The 344-residue follistatin precursor, which yields mature circulating follistatin (FS315) after its signal peptide is cut; the human evidence is AAV1-FS344 gene therapy delivering the gene, not an injected protein.

    Evidence: Preclinical

  • GHRP-2

    Synthetic hexapeptide ghrelin-receptor agonist (pralmorelin, KP-102) that raised GH and food intake 36% in healthy men (n=7); approved in Japan as a single-dose GH-deficiency diagnostic (GHRP Kaken 100).

    Evidence: Clinical

  • GHRP-6

    First synthetic GH-releasing hexapeptide (Bowers 1984); raised GH dose-dependently and synergized with GHRH in normal men (n=18). Appetite and gut-motility effects are documented in rodents.

    Evidence: Clinical

  • Hexarelin

    Highly potent synthetic hexapeptide GH secretagogue that also showed direct cardioprotective effects in animal work; desensitizes the GH axis with continuous use.

    Evidence: Clinical

  • IGF-1 DES

    Truncated IGF-1 missing the N-terminal Gly-Pro-Glu; about 10x as potent as IGF-1 on cultured cells, because losing Glu3 removes most IGF-binding-protein binding. Occurs naturally in colostrum, brain and uterus.

    Evidence: Preclinical

  • IGF-1 LR3

    IGF-1 analog with Glu3 replaced by Arg plus a 13-residue N-terminal extension, which binds IGF-binding proteins poorly; in animals it is 2 to 3x as potent as IGF-1 at lowering glucose and is cleared faster, not slower.

    Evidence: Preclinical

  • Ipamorelin

    Pentapeptide ghrelin-receptor agonist that released GH without raising ACTH or cortisol in swine (Raun 1998); human data are a PK study (n=40) and one negative phase 2 trial in postoperative ileus (n=114).

    Evidence: Preclinical

  • MGF (IGF-1 Ec)

    The IGF-1Ec splice variant and its synthetic 24-residue E-domain peptide; mRNA rises in loaded human muscle, but the peptide's proliferative effect failed to replicate and no endogenous peptide has been isolated.

    Evidence: Preclinical

  • MK-2866

    Enobosarm (ostarine), a non-steroidal selective androgen receptor modulator - not a peptide; human trials at 1-3 mg daily showed gains in lean body mass and physical function.

    Evidence: Clinical

  • MK-677

    Ibutamoren, an orally active non-peptide ghrelin receptor agonist that raises GH and IGF-1 in human trials; studied for lean mass, bone density, and sleep quality.

    Evidence: Clinical

  • PEG-MGF

    PEGylated version of mechano growth factor (the IGF-1Ec splice variant), sold as a research chemical; no published pharmacology or human data exist for the PEGylated form.

    Evidence: Anecdotal

Other categories